Benchmarking AlphaMissense Pathogenicity Predictions Against Cystic Fibrosis Variants.
Benchmarking AlphaMissense Pathogenicity Predictions Against Cystic Fibrosis Variants.
复制标题
针对囊性纤维化变异体的 AlphaMissense 致病性预测进行基准测试。
DOI:
10.1101/2023.10.05.561147
复制
发表时间:
2023
期刊:
影响因子:
--
通讯作者:
Plate,Lars
中科院分区:
文献类型:
--
作者:
McDonald,EliFritz;Oliver,KathrynE;Schlebach,JonathanP;Meiler,Jens;Plate,Lars
Variants in the cystic fibrosis transmembrane conductance regulator gene (CFTR) result in cystic fibrosis–a lethal autosomal recessive disorder. Missense variants that alter a single amino acid in the CFTR protein are among the most common cystic fibrosis variants, yet tools for accurately predicting molecular consequences of missense variants have been limited to date. AlphaMissense (AM) is a new technology that predicts the pathogenicity of missense variants based on dual learned protein structure and evolutionary features. Here, we evaluated the ability of AM to predict the pathogenicity of CFTR missense variants. AM predicted a high pathogenicity for CFTR residues overall, resulting in a high false positive rate and fair classification performance on CF variants from the CFTR2.org database. AM pathogenicity score correlated modestly with pathogenicity metrics from persons with CF including sweat chloride level, pancreatic insufficiency rate, andPseudomonas aeruginosainfection rate. Correlation was also modest with CFTR trafficking and folding competencyin vitro. By contrast, the AM score correlated well with CFTR channel functionin vitro–demonstrating the dual structure and evolutionary training approach learns important functional information despite lacking such data during training. Different performance across metrics indicated AM may determine if polymorphisms in CFTR are recessive CF variants yet cannot differentiate mechanistic effects or the nature of pathophysiology. Finally, AM predictions offered limited utility to inform on the pharmacological response of CF variants i.e.,theratype. Development of new approaches to differentiate the biochemical and pharmacological properties of CFTR variants is therefore still needed to refine the targeting of emerging precision CF therapeutics.
登录
查看更多内容
DOI:
10.1016/0167-8817(87)90039-3
发表时间:
1987
期刊:
Mutation research
影响因子:
--
作者:
Smith,KC;Sharma,RC
通讯作者:
Sharma,RC
影响因子:
3.4
作者:
Mudgett,JS;Manzella,JM;Taylor,WD
通讯作者:
Taylor,WD
影响因子:
3.3
作者:
Mahan,MJ;Roth,JR
通讯作者:
Roth,JR
影响因子:
2.6
作者:
R. Roberts;P. Strike
通讯作者:
P. Strike
DOI:
--
发表时间:
1982
影响因子:
11.1
作者:
S. Schmid;M. Daune;R. Fuchs
通讯作者:
R. Fuchs